Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 10/20 | 0.41 |
| ▸ | MAOA | P21397 | 6/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.34 |
| ▸ | PPIB | P23284 | 1/20 | 0.34 |
| ▸ | PPIA | P62937 | 1/20 | 0.34 |
| ▸ | PPID | Q08752 | 1/20 | 0.34 |
| ▸ | PPIG | Q13427 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3872795 | 0.81 | EPHX2 (0.47) | KDM1AMAOAMAOBEPHX2MAPT | |
| SCHEMBL3872037 | 0.79 | KDM1A (0.49) | KDM1AMAOAMAOBDHODHACKR3 | |
| SCHEMBL3871554 | 0.76 | KDM1A (0.40) | KDM1AMAOAMAOBDHODHHDAC1 | |
| SCHEMBL13938680 | 0.72 | DHODH (0.40) | KDM1AMAOAMAOBDHODHHDAC1 | |
| SCHEMBL3871781 | 0.72 | KDM1A (0.45) | KDM1AMAOAMAOBDHODHHDAC1 | |
| SCHEMBL3872607 | 0.70 | ADORA2A (0.48) | KDM1ADHODH | |
| Trifluoroacetic Acid SCHEMBL3871552 | 0.69 | KDM1A (0.57) | KDM1AMAOAMAOB | |
| SCHEMBL529220 | 0.68 | KDM1A (0.64) | KDM1AMAOB | |
| SCHEMBL529221 | 0.68 | KDM1A (0.64) | KDM1AMAOB | |
| SCHEMBL527379 | 0.68 | KDM1A (0.64) | KDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642620-B2 | Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals | SANOFI (FR) | 2014-02-04 | — | — | US | disclosed |
| EP-1904476-B1 | HETEROARYL-SUBSTITUTED AMIDES COMPRISING AN UNSATURATED OR CYCLIC LINKER GROUP, AND THEIR USE AS PHARMACEUTICALS | SANOFI AVENTIS (FR) | 2009-02-25 | — | — | EP | disclosed |
| US-20080167342-A1 | Heteroaryl-Substituted Amides Comprising An Unsaturated Or Cyclic Linker Group, And Their Use As Pharmaceuticals | SANOFI-AVENTIS (FR) | 2008-07-10 | — | — | US | disclosed |
| EP-1904476-A1 | HETEROARYL-SUBSTITUTED AMIDES COMPRISING AN UNSATURATED OR CYCLIC LINKER GROUP, AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2008-04-02 | — | — | EP | disclosed |
| EP-1741708-A1 | Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals | Sanofi-Aventis Deutschland GmbH (DE) | 2007-01-10 | — | — | EP | disclosed |
| WO-2007000248-A1 | HETEROARYL-SUBSTITUTED AMIDES COMPRISING AN UNSATURATED OR CYCLIC LINKER GROUP, AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167342-A1 | Heteroaryl-Substituted Amides Comprising An Unsaturated Or Cyclic Linker Group, And Their Use As Pharmaceuticals | TBXAS1, PTGIS, NOS2 | KDM1A 1391/4885MAOA 238/4885MAOB 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.